IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against TransEnterix Inc. (“TransEnterix” or the “Company”) (Nasdaq: TRXC). Investors who purchased or otherwise acquired shares between February 10, 2016 and May 10, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm prior to the August 1, 2016, lead plaintiff motion deadline.
If you purchased shares of TransEnterix during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, there were deficiencies within the Company's 510(k) submission regarding the SurgiBot that undermined the likelihood that the SurgiBot would receive FDA clearance, which would leave the Company unable to commercialize the SurgiBot in 2016 and would impair the Company's ability to obtain approval for and commercialize its other robotic surgery platform in the United States.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.